Hiroshi Ishiguro

Hidaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 323 publications

Modulating Multimodal Emotional and Social Perception of Huggable Robot Expressions Through Chest Haptics.

Modulating Multimodal Emotional and Social Perception of Huggable Robot Expressions Through Chest Haptics.

Journal: IEEE transactions on haptics

Published: August 13, 2026

Social Role-based Training Using a Computer Graphics Avatar in a Real-world Commercial Setting for Individuals with Autism Spectrum Disorder: A Quasi-experimental Study.

Social Role-based Training Using a Computer Graphics Avatar in a Real-world Commercial Setting for Individuals with Autism Spectrum Disorder: A Quasi-experimental Study.

Journal: Journal of medical Internet research

Published: August 04, 2026

Feasibility of a randomised controlled trial comparing opioid dose escalation with low-dose methadone addition for refractory cancer pain: JORTC-PAL23/NCCH2309 - protocol.

Feasibility of a randomised controlled trial comparing opioid dose escalation with low-dose methadone addition for refractory cancer pain: JORTC-PAL23/NCCH2309 - protocol.

Journal: BMJ open

Published: August 04, 2026

Study Protocol for Feasibility Randomized, Placebo-Controlled Trial of Efficacy of Midazolam as the Second-Line Treatment for Dyspnea in Patients with Advanced Cancer.

Study Protocol for Feasibility Randomized, Placebo-Controlled Trial of Efficacy of Midazolam as the Second-Line Treatment for Dyspnea in Patients with Advanced Cancer.

Journal: Palliative medicine reports

Published: May 19, 2026

A case of recurrent breast cancer with severe hepatic dysfunction: Integrating narrative-based medicine and clinical decision-making.

A case of recurrent breast cancer with severe hepatic dysfunction: Integrating narrative-based medicine and clinical decision-making.

Journal: Palliative & supportive care

Published: May 14, 2026

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10).

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10).

Journal: BMJ open

Published: May 13, 2026

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 24, 2026

An avatar motion system for realizing gesture functions.

An avatar motion system for realizing gesture functions.

Journal: Scientific reports

Published: April 13, 2026

Compartment-Specific CD138 Expression Defines an Aggressive Breast Cancer Phenotype with Distinct Transcriptomic Features.

Compartment-Specific CD138 Expression Defines an Aggressive Breast Cancer Phenotype with Distinct Transcriptomic Features.

Journal: Cancers

Published: April 02, 2026

Effects of Glucagon-Like Peptide 1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide on Fluid Secretion in Guinea-Pig Pancreatic Duct Cells.

Effects of Glucagon-Like Peptide 1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide on Fluid Secretion in Guinea-Pig Pancreatic Duct Cells.

Journal: Pancreas

Published: March 25, 2026

Baseline Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in PD-L1-positive Advanced Triple-negative Breast Cancer With Immune-checkpoint-inhibitor Treatment.

Baseline Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in PD-L1-positive Advanced Triple-negative Breast Cancer With Immune-checkpoint-inhibitor Treatment.

Journal: Cancer diagnosis & prognosis

Published: March 17, 2026

Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan.

Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan.

Journal: BMC cancer

Published: February 06, 2026

Showing 1-12 of 323

Last Updated: 09/26/2026